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Abstract
Background: Malignant gliomas are lethal cancers, highly dependent on angiogenesis and
treatment options and prognosis still remain poor for patients with recurrent glioblastoma
multiforme (GBM). Ephs and ephrins have many well-defined functions during embryonic
development of central nervous system such as axon mapping, neural crest cell migration, hindbrain
segmentation and synapse formation as well as physiological and abnormal angiogenesis.
Accumulating evidence indicates that Eph and ephrins are frequently overexpressed in different
tumor types including GBM. However, their role in tumorigenesis remains controversial, as both
tumor growth promoter and suppressor potential have been ascribed to Eph and ephrins while the
function of EphA7 in GBM pathogenesis remains largely unknown.
Methods: In this study, we investigated the immunohistochemical expression of EphA7 in a series
of 32 primary and recurrent GBM and correlated it with clinical pathological parameters and
patient outcome. In addition, intratumor microvascular density (MVD) was quantified by
immunostaining for endothelial cell marker von Willebrand factor (vWF).
Results: Overexpression of EphA7 protein was predictive of the adverse outcome in GBM
patients, independent of MVD expression (p = 0.02). Moreover, high density of MVD as well as
higher EphA7 expression predicted the disease outcome more accurately than EphA7 variable
alone (p = 0.01). There was no correlation between MVD and overall survival or recurrence-free
survival (p > 0.05). However, a statistically significant correlation between lower MVD and tumor
recurrence was observed (p = 0.003).
Conclusion: The immunohistochemical assessment of tissue EphA7 provides important
prognostic information in GBM and would justify its use as surrogate marker to screen patients for
tyrosine kinase inhibitor therapy.
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The incidence of brain tumors worldwide is about 7 in
100,000 per year [1,2]. Glioblastoma multiforme (GBM),
the most aggressive tumor among malignant gliomas, is
the most common primary brain tumor in adults and rep-
resents a significant source of cancer-related death. GBM
usually recurs despite the most aggressive treatment via
surgical resection of the tumor followed by radiation and/
or chemotherapy [1,2]. The poor prognosis of patients
with GBM (median survival ranging from 9 to 12 months,
5-year survival rate close to 0%) mandates the exploration
of novel molecular mechanisms that might contribute to
the pathogenesis of this disease and its resistance to ther-
apy with the purpose of therapeutic targeting [1-3].
Receptor tyrosine kinases (RTKs) are known to be impor-
tant regulators of cellular growth controlling cell prolifer-
ation, differentiation and migration [4,5]. The Eph
receptors and their ligands, ephrins, represent the largest
known family of RTKs. Their role has been largely studied
during the development of nervous system. They are
involved in the development of central nervous system,
including axon guidance, axon fasciculation, neural crest
cell migration, hindbrain segmentation, vasculogenesis
and neuronal cell survival during embryonic develop-
ment [6-13]. Eph receptors and ephrin ligands are classi-
fied into A and B subfamily, on the basis of their
sequence, homologies, structures, and binding affinities.
EphA receptors bind the glycosylphosphatidylinositol
(GPI)-anchored ephrin-A ligands, whereas EphB receptors
bind the transmembrane ephrin-B ligands, whose cyto-
plasmic domain is capable to engage in various signaling
activities; an exception is the EphA4 receptor that binds
ephrin-B2 and ephrin-B3 as well as ephrin-A ligands [14-
16]. Moreover, these RTKs have the ability to induce both
forward and reverse (bi-directional) signaling between
adjacent interacting cells.
To date, various studies have investigated the involvement
of the Eph-RTKs in several pathogenetic processes in the
nervous system. EphB2 and ephrin-B2 signaling partici-
pate in the glial scarring process after spinal cord trauma
[17]. The phosphorylation ratio of R-Ras was closely
linked to the phosphorylation ratio of EphB2 in glioblas-
toma tissues [18]. Additionally, the phosphorylation ratio
of EphB2 is an important mechanism that mediates gli-
oma cell migration and invasion [19]. Ephrin-B2 and
EphB4 were overexpressed by endothelial cells of human
malignant gliomas [20]. Ephrin-B3 was also demon-
strated as an important factor regulating glioma cell inva-
sion through Rac1 GTPase [21]. EphA2 protein was
overexpressed in GBM and anaplastic astrocytoma tissues
and was identified as a novel target for the development
of glioma vaccines [22,23]. Another group confirmed
overexpression of EphA2 expression in GBM cells, proba-
bly through decreased interaction between EphA2 recep-
tor and its inhibitory ligand ephrin-A1 in malignant cells
[19].
EphA7 (formerly known as Mdk1/Ebk/Ehk) is highly con-
served in vertebrates from fish to human [24]. It is widely
expressed in embryonic tissues, especially developing cen-
tral nervous system [25]. EphA7 cooperates with other
EphA receptors in cell signaling, but in contrast to other
Eph receptors, it contains two developmentally regulated
isoforms: a full-length version containing the intracellular
tyrosine kinase domain and a truncated form that lacks
this domain [26]. Immunoreactivity for the full-length
wild type receptor is found in all cell populations express-
ing EphA7 mRNA in mouse embryo heads and develop-
ing brain, while the truncated EphA7 is absent in the
embryos. Interestingly, both isoforms show striking distri-
butions in adult mouse brain [27]. The full-length EphA7
is strongly expressed in neuropil; in contrast the truncated
EphA7 is conspicuous on cell bodies and proximal den-
drites of a limited number of neuronal types [28]. The
truncated form of EphA7 acts as a dominant negative
antagonist, suppressing tyrosine phosphorylation of the
full-length EphA7 receptor and shifts the cellular response
from repulsion to adhesion. Additionally, EphA7 is prob-
ably essential during closure of the neural folds, since
EphA7-null mice displayed lack of the neural folds resem-
bling anencephaly in man [29]. Moreover, EphA7 has
been identified as an important molecular cue expressed
after spinal cord injury, implicated in glial apoptosis [30].
Recent work indicated EphA7 as an important mediator of
neural progenitor apoptosis during brain development
[31]. However, little is currently known about its role in
brain tumor angiogenesis and pathogenesis.
In the present study, we investigated the immunohisto-
chemical expression of EphA7 and correlated it with clin-
ical pathological parameters and tumor vascularity. We
provide evidence that EphA7 is overexpressed in GBM and
suggest that this receptor might be used as a new diagnos-




Tumor samples of 32 patients with histologically con-
firmed GBM, WHO IV, (26 primary GBM, 6 recurrent
GBMs and 10 normal brain samples) were obtained from
the Department of Neuropathology, Marburg University
Hospital, Germany. Approval for immunohistochemical
study conduct in this GBM tissue bank had been obtained
by the university authorities together with the signed con-
sent of the patients. The patients underwent surgery and
received adjuvant radiation therapy combined with chem-
otherapy using the schema ACNU and VM-26. The firstPage 2 of 9
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Subsequent follow-ups were scheduled every 3 months. In
addition to clinical investigations and monitoring of indi-
ces of recurrence, a radiological examination was per-
formed to detect possible relapses. Disease progression
was defined according to WHO criteria by either an
increase of at least 25% in tumor size or any new tumor
identified by CT or MRI scan. Normal brain samples,
which included cortex and white matter, were obtained
from autopsy cases without any evidences of brain tumor
or other brain disease. Totally, five cases of male and five
cases of female (age ranging from 27 to 70 years, average:
48.6 years) were obtained.
Immunohistochemistry
Immunohistochemical studies were performed on forma-
lin fixed, paraffin-embedded tissue. Samples slides were
passed through a sequence of Roti-histol (Carl Roth, Karl-
sruhe, Germany) and graded alcohol and then rinsed in
phosphate-buffered saline (PBS). After rinsing with PBS,
the slides were treated with 3% hydrogen peroxide in PBS
for 15 min at room temperature in order to abolish
endogenous peroxidase activity. Subsequently, the slides
were treated with 5% blocking serum for 1 hour. Follow-
ing this, slides were incubated overnight at 4°C with a
rabbit anti-human EphA7 polyclonal antibody (H-55)
against amino acids of human EphA7 (1:100 dilution;
Santa Cruz Biotechonology, Heidelberg, Germany), or
rabbit anti-human Factor VIII (von Willebrand Factor,
vWF) polyclonal antibody (1:400 dilution; Dako Cytoma-
tion, Carpinteria, CA). In negative controls, the primary
antibody was replaced with 1 × PBS. The signal was
enhanced by using biotinylated polyclonal goat-anti-rab-
bit IgG with streptavidin-HRP (Dako Cytomation,
Carpinteria, CA) for 30 minutes. The colour was devel-
oped after 5 minutes incubation with 3,3-diaminobenzi-
dine (DAB) solution and sections were weakly
counterstained with hematoxylin for 10 seconds.
Evaluation of EphA7 expression
The membranous and cytoplasmic expression of EphA7
on tumor cells was assessed at a ×400 magnification. The
assigned score first reflects the staining intensity A (0, neg-
ative; 1, weak; 2, moderate; 3, high) and second the per-
centage of positive cells B (0, no positive cells; 1, <25%
positive cells; 2, 25 to 50% positive cells; 3, >50% positive
cells). An overall score of 3 is defined as positive staining.
The scoring was performed separately by two independent
observers who were blinded to the clinical data. Any dis-
crepancies were resolved on the conference microscope.
Evaluation of MVD at "hot spot" of tumor angiogenesis
Tumor angiogenesis can be reflected by MVD in the most
vascularised areas of tumor tissue. MVD, as highlighted by
factor VIII-related antigen immunostaining, was assessed
without knowledge of the patient's clinical outcome, as
described by Weidner et al [32]. Briefly, each slide was
scanned at low magnification (×100) to identify four
areas with the highest density of microvessel (hot-spots).
Each hot-spot was then evaluated at high power magnifi-
cation (×200) for the number of stained microvessels per
field in a 0.7386 mm2 surface area. vWF-positive stained
blood vessels with a complete lumen as well as cell clus-
ters without lumina were considered as individual micro-
vessels. The final microvessel score was the average of
vessel counts from four fields assessed by a high power
magnification field (×200).
Statistical analysis
Survival curves were estimated using the Kaplan-Meier
method. The distributions of survival were compared
using the log rank test. The chi-square test was employed
to determine the association between EphA7 expression
intensity on tumor cells and MVD. A p-value < 0.05 was
considered to be statistically significant. All statistical
analysis was performed using SPSS software.
Results
Demographic factors
32 patients with histologically confirmed primary and
recurrent GBM, WHO grade IV, were studied. The mean
age at diagnosis was 54.3 years (range 31–71). No signifi-
cant difference in age distribution between male (21
cases) and female (11 cases) was detected. All of the 32
patients showed a relapse between 1 and 22 months after
surgery and subsequently died of the disease (median sur-
vival 15 months).
EphA7 immunoreactivity in GBM and normal brain tissues
In 22 of 32 patients, EphA7 immunoreactivity was
observed on the prominent membrane and cytoplasm of
tumor cells showing different intensities of EphA7 pro-
tein. Representative photomicrographs illustrating speci-
mens with negative and strong EphA7 expression in
tumor cells are presented in Fig. 1A and 1B, respectively.
EphA7 protein expression in glioma cells of 10 normal
brain tissues analyzed was undetectable as it was shown in
Fig. 1E. Of the 32 GBM analyzed, strong expression of
EphA7 (staining intensities of from 6 to 9) was observed
in 14 cases (43.7%) of GBM. The staining was specific in
both tumor and endothelial cells, with minimal staining
of surrounding connective tissues.
EphA7 associated with MVD in GBM
All tumors were stained with vWF and microvessels were
counted as a measure of tumor's angiogenic activity. The
median MVD of 30 vessels was treated as a cutpoint. High
MVD was noted in areas where overexpression of EphA7
was marked (Table 1). Representative examples of low or
high MVD were showed in Fig 1C and 1D, respectively.Page 3 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:79 http://www.biomedcentral.com/1471-2407/8/79There was a statistically significant correlation between
expression of EphA7 and MVD in the tumors (P = 0.004,
Table 1).
EphA7 immunoreactivity predicted overall survival but not 
recurrence-free survival
The median survival of patients with positive EphA7
expression was reduced in comparison with patients with
negative EphA7 expression. EphA7 protein expression
showed an inverse correlation with the overall survival (p
= 0.02, Fig. 2A). However, the level of EphA7 expression
did not emerge as a prognostic factor for recurrence-free
survival of GBM patients (p = 0.51, Fig. 2B). There was no
correlation between MVD and overall survival or recur-
rence-free survival (p > 0.05, data not shown). We further
explored the prognostic relationship using EphA7 in com-
bination with MVD. The study cohort could be divided
into 3 groups based on expression for EphA7 and MVD
combination: EphA7(+)/high MVD (n = 12), EphA7(+)/
low MVD (n = 10), EphA7(-)/high MVD (n = 0), EphA7(-
Immunohistochemical demonstration of EphA7 protein expression and blood vessels in GBMFigure 1
Immunohistochemical demonstration of EphA7 protein expression and blood vessels in GBM. Representative 
examples of GBM showing negative staining in tumor cells (A) or strong membranous and cytoplasmic staining in both tumor 
cells and endothelial cells (B). MVD in GBM by immunohistochemical staining for vWF, microvessels are represented by brown 
clusters, which stand out sharply from other tissues. Low tumor vascularity (C) in GBM with low expression of EphA7 as 
shown A. In contrast, microvessel density was relatively high (D) in GBM with high expression of EphA7 as shown B. Negative 
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MVD as well as EphA7 expression predicted for the disease
outcome more accurately than Eph variable alone (p =
0.01).
Clinical features associated with EphA7 or MVD
Statistical correlation was detected between the expression
levels of EphA7 or MVD and clinical pathological param-
eters such as age, gender and tumor status (Table 2). A sta-
tistically significant correlation between higher MVD and
tumor recurrence was observed (p = 0.003). In addition,
positive EphA7 expression was associated with increased
age of patients (>55 years, p = 0.003).
Discussion
There is currently an urgent need for development of alter-
native, effective diagnostic and therapeutic approaches to
GBM. The survival of patients with GBM may depend on
the identification of novel targets. EphA2 receptor has
already been recognized as a potential molecular marker
and target in GBM for the development of novel biologi-
cal therapeutic agents [22,23,33]. Whereas several studies
in recent years have clearly indicated that altered expres-
sion of Eph receptors and ephrin ligands is associated
with increased potential for tumor growth, angiogenesis,
metastasis and adverse outcome [34-42], few studies have
addressed the role of EphA7 in tumor pathogenicity. By
employing immunohistochemical techniques we have
found that EphA7 protein is predictive for the outcome of
patients with GBM, independent of MVD expression. The
data in the present study revealed for the first time a strong
correlation between EphA7 overexpression and patient
survival.
Hafner C, et al. found that EphA7 is highly expressed in
kidney vasculature [43]. The mRNA of EphA7 is strongly
upregulated in hepatocellular carcinoma as compared
with healthy liver tissue and is downregulated in colon
carcinomas. EphA7 is also transcriptionally activated in
lung cancer [44]. Furthermore, overexpression of EphA7
protein is frequently found in younger patients and in
patients with advanced gastric carcinoma [45]. EphA7
expression is frequently silenced in human colorectal car-
cinoma by aberrant promoter methylation [46]. EphA7 is
located on 6q16.1, a region in close proximity to the chro-
mosome 6 breakpoint found in various types of cancer
[47]. Although our findings are not consistent with Wang
et al, who found a significant downregulation of EphA7 in
colorectal carcinoma [46], they are in line with previous
reports reporting a tumor promoter role in lung cancer
and hepatocellular carcinoma [43,44], implicating tumor
type-specific function for different Eph family members.
Eph receptors expressed in different cell types may have
opposite effects due to cell-type specific intracellular sign-
aling pathway [4]. Indeed, EphB4 receptor has been iden-
tified as a tumor suppressor in breast cancer, through
activation of Abl-Crk antioncogenic pathway [48], while
the same receptor presented a tumorigenic potential in
mesothelioma, favoring uncontrolled cell growth, migra-
tion, and tumor progression [49]. Moreover, membrane-
bound ephrins trigger Eph receptor phosphorylation,
while soluble forms can bind to Eph receptor, but do not
trigger receptor activation [50]. Murine and human
peripheral lymphocytes secrete a truncated form of EphA7
[51]. Truncated Eph receptors retaining their ligand-bind-
ing capacity have been shown to block activation of the
full-length receptor [52]. Promoter hypermethylation and
silencing of EphA7 in mature B-cell lymphomas may serve
to eliminate the inhibitory activity of secreted EphA7 on
tumor-promoting EphA7 receptor signaling, thus enhanc-
ing tumor cell spread and recruitment of accessory cells
able to promote tumor growth [51]. A recent study on sig-
naling pathways involved in EphA7 RTK reported that
direct EphA7 knockdown can result in attenuation of
ERK1/2 phosphorylation and induce apoptosis of leuke-
mia cells, suggesting the impact of EphA7 on the growth
of tumor cells [45]. It is of interest that positive EphA7
expression was closely associated with increased age of
patients (>55 years). Whether this is a random finding or
not deserves further investigation.
The unfavorable prognostic influence of EphA7 in GBM
could be attributed to the well-recognised role of Eph
RTKs in tumor angiogenesis. Indeed, in this study a statis-
tically significant correlation between expression of
EphA7 and MVD was noted in GBM specimens. Another
important observation was EphA7 overexpression in both
vasculature as well as tumor cells. The process of angio-
genesis plays a central role in tumor growth and in the
development of distant metastases by facilitating the entry
of cells into circulation [52-55]. A vast biochemical and
genetic evidence has implicated the critical role of Eph/
ephrin signaling in angiogenesis, despite of VEGFR2 and
Tie2 receptors long been recognized as key players in this
process [53,54]. Angiogenetic activity can be measured
histologically by MVD, which has been shown to be an
independent prognostic parameter in various malignan-
cies including gliomas [56-58]. However, other studies on
Table 1: Relationship between EphA7 expression and intratumor 
microvessel density in 32 primary and recurrent GBM.




High 0 12 0.004
MVD: microvessel density, N: number of patients. The median MVD 
of 30 vessels was used as a cutpoint.Page 5 of 9
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Kaplan-Meier curve for overall survival and recurrence-free survival in 32 patients based on EphA7 expression and MVD indexFigure 2
Kaplan-Meier curve for overall survival and recurrence-free survival in 32 patients based on EphA7 expression 
and MVD index. (A) Increased EphA7 expression was significantly associated with dead of disease (P = 0.02 by log-rank test), 
when positive EphA7 (score = 4–9) expressing tumors were plotted against negative EphA7 expressing tumors (score = 0–3). 
(B) EphA7 expression revealed no significance for recurrence-free survival. (C) EphA7 expression in combination with high 




BMC Cancer 2008, 8:79 http://www.biomedcentral.com/1471-2407/8/79angiogenesis of glioblastomas suggested the limited usage
of MVD as prognostic parameter due to the complexity of
the microvascular network in GBM [59,60]. Although no
correlation between MVD and overall survival or recur-
rence-free survival was found in our study, we observed a
statistically significant correlation between lower MVD
and tumor recurrence. Further prospective studies with
large numbers of patients are, however, needed to fully
clarify the clinical implications of MVD in GBM recur-
rence.
Conclusion
Taken together, our data illustrated that EphA7 could be a
potential candidate as a prognostic tumor marker and a
new targeted therapeutic assessment in primary and recur-
rent GBM. Based on our findings, there might be a possi-
ble relationship between EphA7 and tumor
neovascularization. Recent data demonstrating inhibition
of angiogenesis through EphA receptor blockade in two
different animal tumor models are consistent with our
observation [52]. Additional experimental work is neces-
sary to unveil the biologic pathway linking Eph/ephrins
with tumor growth in cancer cells and tumor-associated
vessels of GBM and further studies are needed before
EphA7 becomes established as an important prognostic
and predictive tool in GBM. Ultimately, specific EphA7
inhibitors may prove to be of therapeutic value.
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